<VariationArchive VariationID="1699144" VariationName="NM_000314.8(PTEN):c.658_659dup (p.Leu220_Lys221insTer)" VariationType="Duplication" Accession="VCV001699144" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-23" DateCreated="2022-08-08" MostRecentSubmission="2024-07-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1691518" VariationID="1699144">
      <GeneList>
        <Gene Symbol="PTEN" FullName="phosphatase and tensin homolog" GeneID="5728" HGNC_ID="HGNC:9588" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>10q23.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="87863625" stop="87971930" display_start="87863625" display_stop="87971930" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NW_013171807.1" start="79449" stop="187719" display_start="79449" display_stop="187719" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="89623194" stop="89728531" display_start="89623194" display_stop="89728531" Strand="+" />
          </Location>
          <OMIM>601728</OMIM>
          <Haploinsufficiency last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000314.8(PTEN):c.658_659dup (p.Leu220_Lys221insTer)</Name>
      <CanonicalSPDI>NC_000010.11:87957875:CT:CTCT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>10q23.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="87957875" stop="87957876" display_start="87957875" display_stop="87957876" variantLength="2" positionVCF="87957875" referenceAlleleVCF="G" alternateAlleleVCF="GCT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="89717632" stop="89717633" display_start="89717632" display_stop="89717633" variantLength="2" positionVCF="89717632" referenceAlleleVCF="G" alternateAlleleVCF="GCT" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001304717.5" sequenceAccession="NM_001304717" sequenceVersion="5" change="c.1177_1178dup">
            <Expression>NM_001304717.5:c.1177_1178dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001291646.4" sequenceAccession="NP_001291646" sequenceVersion="4" change="p.Leu393_Lys394insTer">
            <Expression>NP_001291646.4:p.Leu393_Lys394insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001304718.2" sequenceAccession="NM_001304718" sequenceVersion="2" change="c.67_68dup">
            <Expression>NM_001304718.2:c.67_68dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001291647.1" sequenceAccession="NP_001291647" sequenceVersion="1" change="p.Leu23_Lys24insTer">
            <Expression>NP_001291647.1:p.Leu23_Lys24insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_311" sequenceAccession="LRG_311">
            <Expression>LRG_311:g.99438_99439dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_311t1" sequenceAccession="LRG_311t1">
            <Expression>LRG_311t1:c.658_659dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.10" sequenceAccession="NC_000010" sequenceVersion="10" change="g.89717633_89717634dup" Assembly="GRCh37">
            <Expression>NC_000010.10:g.89717633_89717634dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.11" sequenceAccession="NC_000010" sequenceVersion="11" change="g.87957876_87957877dup" Assembly="GRCh38">
            <Expression>NC_000010.11:g.87957876_87957877dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007466.2" sequenceAccession="NG_007466" sequenceVersion="2" change="g.99438_99439dup">
            <Expression>NG_007466.2:g.99438_99439dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000314.8" sequenceAccession="NM_000314" sequenceVersion="8" change="c.658_659dup" MANESelect="true">
            <Expression>NM_000314.8:c.658_659dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000305.3" sequenceAccession="NP_000305" sequenceVersion="3" change="p.Leu220_Lys221insTer">
            <Expression>NP_000305.3:p.Leu220_Lys221insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2132276566" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000314.8(PTEN):c.658_659dup (p.Leu220_Lys221insTer) AND PTEN hamartoma tumor syndrome" Accession="RCV002273001" Version="3">
        <ClassifiedConditionList TraitSetID="2131">
          <ClassifiedCondition DB="MedGen" ID="C1959582">PTEN hamartoma tumor syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-05-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-05-21" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-08-08" MostRecentSubmission="2024-07-23">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">31594918</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2131" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10363" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">PTEN hamartoma tumor syndrome</ElementValue>
                <XRef ID="MONDO:0017623" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PTEN Hamartomatous Tumour Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHTS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558905" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551654" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552184" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%. The risk for endometrial cancer may approach 28%. BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis. PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses. Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</Attribute>
                <XRef ID="NBK1488" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12800" />
                <XRef ID="12800" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">PTEN-related disorders</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301661</ID>
                <ID Source="BookShelf">NBK1488</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <Citation Type="general" Abbrev="NCCN, 2014">
                <ID Source="PubMed">25190698</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="306498" DB="Orphanet" />
              <XRef ID="C1959582" DB="MedGen" />
              <XRef ID="D006223" DB="MeSH" />
              <XRef ID="MONDO:0017623" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5003339" SubmissionDate="2024-07-18" DateLastUpdated="2024-07-23" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000314_4_PTEN_c_658_659dupCT" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002557533" DateUpdated="2024-07-23" DateCreated="2022-08-08" Type="SCV" Version="2" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-05-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">31594918</ID>
          </Citation>
          <Comment>Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0107 - This gene is known to be associated with autosomal dominant disease. (N) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (exon 7 of 9). (P) 0251 - Variant is heterozygous. (N) 0301 - Variant is absent from gnomAD. (P) 0701 - Comparable variants have very strong previous evidence for pathogenicity (Decipher, ClinVar, Busch, R. M. et al. (2019)) (P) 0807 - Variant has not previously been reported in a clinical context. (N) 0905 - No segregation evidence has been identified for this variant. (N) 1007 - No published functional evidence has been identified for this variant. (N) 1208 - Inheritance information for this variant is not currently available. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTEN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_2566</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000314.4:c.658_659dupCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0017623" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_32</SubmissionName>
          <SubmissionName>submission_45</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5003339" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0017623" MappingRef="MONDO">
        <MedGen CUI="C1959582" Name="PTEN hamartoma tumor syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

